中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 12
Dec.  2022
Turn off MathJax
Article Contents

Porto-sinusoidal vascular disease——A novel entity of portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.12.032
Research funding:

Shenzhen Science and Technology Innovation Commission Fundamental Research Key Projects of 2018 (JCY20180508153013853)

More Information
  • Corresponding author: YANG Dongye, yangdy@hku-szh.org (ORCID: 0000-0003-3558-8871)
  • Received Date: 2022-05-15
  • Accepted Date: 2022-06-20
  • Published Date: 2022-12-20
  • Porto-sinusoidal vascular disease (PSVD) is an entity characterized with portal hypertension (PH) in the absence of cirrhosis, the related risk factors, and imaging evidence of obstructed portal vein, hepatic vein and inferior vena cava. Its prevalence varies significantly between East and West countries. Until now, the etiologies have been classified as autoimmune, hematologic, and prethrombotic conditions, infections, toxins or drugs, and genetic or metabolic disorders. However, the definite cause remains unknown. Diagnosis is based on three histopathological features: obliterative portal venopathy, nodular regenerative hyperplasia, and incomplete septal fibrosis. The clinical manifestations of early PSVD are nonspecific, whereas those at a late stage are similar to cirrhosis. The imaging detection mainly reveals the PH signs and complications, but the liver stiffness is normal or slightly increased, necessitating a liver biopsy for PVSD diagnosis. PSVD treatment is similar to liver cirrhosis; however, the prognosis is better. In order to gain a thorough understanding of PSVD, the epidemiology, pathogenesis, clinical diagnosis, and treatment are discussed in this article.

     

  • loading
  • [1]
    SIMONETTO DA, LIU M, KAMATH PS. Portal hypertension and related complications: diagnosis and management[J]. Mayo Clin Proc, 2019, 94(4): 714-726. DOI: 10.1016/j.mayocp.2018.12.020.
    [2]
    KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: Review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376.
    [3]
    CHOUGULE A, RASTOGI A, MAIWALL R, et al. Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis[J]. Hepatol Int, 2018, 12(2): 158-166. DOI: 10.1007/s12072-018-9857-y.
    [4]
    SCHOUTEN JN, GARCIA-PAGAN JC, VALLA DC, et al. Idiopathic noncirrhotic portal hypertension[J]. Hepatology, 2011, 54(3): 1071-1081. DOI: 10.1002/hep.24422.
    [5]
    DE GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
    [6]
    NICOARǍ-FARCǍU O, RUSU I, STEFǍNESCU H, et al. Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease[J]. World J Gastroenterol, 2020, 26(22): 3000-3011. DOI: 10.3748/wjg.v26.i22.3000.
    [7]
    SCHOUTEN JN, VERHEIJ J, SEIJO S. Idiopathic non-cirrhotic portal hypertension: a review[J]. Orphanet J Rare Dis, 2015, 10: 67. DOI: 10.1186/s13023-015-0288-8.
    [8]
    GIOIA S, NARDELLI S, RIDOLA L, et al. Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis?[J]. World J Hepatol, 2019, 11(8): 613-618. DOI: 10.4254/wjh.v11.i8.613.
    [9]
    AGGARWAL S, FIEL MI, SCHIANO TD. Obliterative portal venopathy: a clinical and histopathological review[J]. Dig Dis Sci, 2013, 58(10): 2767-2776. DOI: 10.1007/s10620-013-2736-4.
    [10]
    GIOIA S, RIGGIO O, NARDELLI S, et al. Identifying patients at high risk of developing non-cirrhotic portal hypertension[J]. Hepat Med, 2021, 13: 105-111. DOI: 10.2147/HMER.S282674.
    [11]
    KOOT BG, ALDERS M, VERHEIJ J, et al. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension[J]. J Hepatol, 2016, 64(4): 974-977. DOI: 10.1016/j.jhep.2015.11.027.
    [12]
    VILARINHO S, SARI S, YILMAZ G, et al. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension[J]. Hepatology, 2016, 63(6): 1977-1986. DOI: 10.1002/hep.28499.
    [13]
    BESMOND C, VALLA D, HUBERT L, et al. Mutations in the novel gene FOPV are associated with familial autosomal dominant and non-familial obliterative portal venopathy[J]. Liver Int, 2018, 38(2): 358-364. DOI: 10.1111/liv.13547.
    [14]
    VISPO E, CEVIK M, ROCKSTROH JK, et al. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients[J]. Clin Infect Dis, 2013, 56(8): 1117-1122. DOI: 10.1093/cid/cit001.
    [15]
    HERNÁNDEZ-GEA V, CAMPRECIÓS G, BETANCOURT F, et al. Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease[J]. J Hepatol, 2021, 75(4): 924-934. DOI: 10.1016/j.jhep.2021.05.014.
    [16]
    BARBERÁ A, RAURELL I, GARCÍA-LEZANA T, et al. Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model[J]. Liver Int, 2020, 40(11): 2732-2743. DOI: 10.1111/liv.14632.
    [17]
    ZUO C, CHUMBALKAR V, ELLS PF, et al. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies[J]. Hepatol Int, 2017, 11(5): 452-460. DOI: 10.1007/s12072-017-9801-6.
    [18]
    CAZALS-HATEM D, HILLAIRE S, RUDLER M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis[J]. J Hepatol, 2011, 54(3): 455-461. DOI: 10.1016/j.jhep.2010.07.038.
    [19]
    JHARAP B, VAN ASSELDONK DP, DE BOER NK, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement[J]. PLoS One, 2015, 10(6): e0120299. DOI: 10.1371/journal.pone.0120299.
    [20]
    GUIDO M, ALVES V, BALABAUD C, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition[J]. Histopathology, 2019, 74(2): 219-226. DOI: 10.1111/his.13738.
    [21]
    RIGGIO O, GIOIA S, PENTASSUGLIO I, et al. Idiopathic noncirrhotic portal hypertension: current perspectives[J]. Hepat Med, 2016, 8: 81-88. DOI: 10.2147/HMER.S85544.
    [22]
    GIOIA S, NARDELLI S, RIDOLA L, et al. Causes and management of non-cirrhotic portal hypertension?[J]. Curr Gastroenterol Rep, 2020, 22(12): 56. DOI: 10.1007/s11894-020-00792-0.
    [23]
    ARORA A, SARIN SK. Multimodality imaging of obliterative portal venopathy: what every radiologist should know[J]. Br J Radiol, 2015, 88(1046): 20140653. DOI: 10.1259/bjr.20140653.
    [24]
    ELKRIEF L, LAZARETH M, CHEVRET S, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension[J]. Hepatology, 2021, 74(1): 364-378. DOI: 10.1002/hep.31688.
    [25]
    FURUICHI Y, MORIYASU F, TAIRA J, et al. Noninvasive diagnostic method for idiopathic portal hypertension based on measurements of liver and spleen stiffness by ARFI elastography[J]. J Gastroenterol, 2013, 48(9): 1061-1068. DOI: 10.1007/s00535-012-0703-z.
    [26]
    ELKRIEF L, HOUSSEL-DEBRY P, ACKERMANN O, et al. Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4): 491-496. DOI: 10.1016/j.clinre.2020.03.016.
    [27]
    DE FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [28]
    SCHUPPAN D, AFDHAL NH. Liver cirrhosis[J]. Lancet, 2008, 371(9615): 838-851. DOI: 10.1016/S0140-6736(08)60383-9.
    [29]
    DE LÉDINGHEN V, VILLATE A, ROBIN M, et al. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4): 480-485. DOI: 10.1016/j.clinre.2020.03.019.
    [30]
    GRUS T, LAMBERT L, GRUSOVÁ G, et al. Budd-chiari syndrome[J]. Prague Med Rep, 2017, 118(2-3): 69-80. DOI: 10.14712/23362936.2017.6.
    [31]
    ILIESCU L, TOMA L, MERCAN-STANCIU A, et al. Budd-Chiari syndrome - various etiologies and imagistic findings. A pictorial review[J]. Med Ultrason, 2019, 21(3): 344-348. DOI: 10.11152/mu-1921.
    [32]
    BISSONNETTE J, GARCIA-PAGÁN JC, ALBILLOS A, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension[J]. Hepatology, 2016, 64(1): 224-231. DOI: 10.1002/hep.28547.
    [33]
    WÖRAN K, SEMMLER G, JACHS M, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(2): e251-e266. DOI: 10.1016/j.cgh.2020.11.039.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Article Metrics

    Article views (1696) PDF downloads(135) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return